2 results

  • cosopt pf

    (dorzolamide hydrochloride and timolol maleate)
    Thea Pharma Inc.
    COSOPT® PF is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who do not adequately respond to beta-blockers. It is typically administered twice daily and offers a different IOP-lowering effect compared to standard therapies.

  • keveyis

    (Dichlorphenamide)
    Xeris Pharmaceuticals, Inc.
    KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and associated variants.